GOTHENBURG, Sweden, June 7, 2012 /CNW/ - Cellectricon is pleased to
announce the appointment of Paul Karila as the company's Head of
Discovery Services. Dr. Karila brings a solid and highly impressive
neuroscience discovery track record to Cellectricon, important for the
company's expansion in bringing state-of-the-art discovery services to
market. Paul has extensive experience of the drug discovery industry
and has held several management positions at AstraZeneca.
The Company's Discovery Services will be based on the proprietary
Cellaxess(R) Elektra platform for automated cellular electric field
manipulation enabling novel screening applications in the CNS and
Cardiovascular therapeutic fields.
Cellectricon's CEO David Burns said: "Cellectricon is delighted with the
appointment of Dr. Karila. We are looking forward to working with
Paul's experience and direction to broaden our cell-based CNS and
Cardiovascular Discovery Services using the Company's strong IP and
technology position to accelerate discovery through collaborations with
our pharmaceutical partners".
Dr. Karila added: "Cellectricon has a strong reputation in the discovery
industry with equally strong customer validation and well-earned
reputation for providing groundbreaking products and services to the
pharmaceutical and life science research markets. Working with the
strong scientific team, I will focus on further developing and
providing outstanding cell-based discovery services to our customers to
accelerate their drug discovery and biological research. "
Cellectricon is a leading provider of advanced cell-based screening
technologies and services to accelerate drug discovery and cell-based
assay research. Our proprietary technologies include leading systems
for high resolution ion-channel screening and cell engineering.
Developed in close collaboration with leaders in the pharmaceutical
industry and esteemed research labs, the Cellaxess(R) Technology
enables scalable field stimulation, compound delivery and transfection
for genomic screening of primary cells, neurones and stem cells. The
Dynaflow(R) Technology advances ion channel research and discovery
SOURCE Cellectricon AB
For further information:
Contact: Susanne Fagerlund, VP Market Communications, Phone: +46(0)733-67-35-15, E-mail: email@example.com